Evidence for non-Mendelian inheritance in spastic paraplegia 7

Hereditary spastic paraplegia is a group of rare motor neuron diseases considered to be inherited in a classical monogenic Mendelian manner. Although the typical inheritance of spastic paraplegia type 7 is autosomal recessive, several reports have suggested that SPG7 variants may also cause autosomal dominant HSP. We aimed to conduct an exome-wide genetic analysis on a large Canadian cohort of hereditary spastic paraplegia patients and controls to examine the association of SPG7 and hereditary spastic paraplegia. In total, 585 hereditary spastic paraplegia patients from 372 families and 1,175 controls, including 580 unrelated individuals, were analyzed for the presence of SPG7 variants. Whole exome sequencing was performed on 400 hereditary spastic paraplegia patients (291 index cases) and all 1,175 controls. After excluding 38 biallelic hereditary spastic paraplegia type 7 patients, the frequency of heterozygous pathogenic/likely pathogenic SPG7 variant carriers (4.8%) among hereditary spastic paraplegia unrelated index cases who underwent WES, was significantly higher than among unrelated controls (1.7%; OR=2.88, 95%CI=1.24-6.66, p=0.009). The heterozygous SPG7 p.(Ala510Val) variant was found in 3.7% of index cases vs. 0.85% in unrelated controls (OR=4.42, 95%CI=1.49-13.07, p=0.005). We identified four heterozygous SPG7 variant carriers with an additional pathogenic variant in genes known to cause hereditary spastic paraplegia, compared to zero in controls (OR=19.58, 95%CI=1.05-365.13, p=0.0031; Fisher Exact test with Haldane-Anscombe correction), indicating potential digenic inheritance. We further identified four families with heterozygous variants in SPG7 and SPG7-interacting genes (CACNA1A, AFG3L2 and MORC2). Out of these, there is especially compelling evidence for epistasis between SPG7 and AFG3L2. The p.(Ile705Thr) variant in AFG3L2 is located at the interface between hexamer subunits, in a hotspot of mutations associated with spinocerebellar ataxia type 28 that affect its proteolytic function. Our results provide evidence for complex inheritance in SPG7-associated hereditary spastic paraplegia, which may include recessive and possibly dominant and digenic/epistasis forms of inheritance.

Introduction cellular processes including organelle biogenesis, intracellular motility, membrane trafficking, protein folding, and proteolysis. The SPG7 gene is comprised of 17 exons with mutational hotspots in exons 11, 13 and 15 (Coarelli et al., 2019). The p.(Ala510Val) variant in exon 11 is a known mutational hotspot in SPG7, which despite relatively high allele frequency (AF) in publicly available databases (0.0027 in control samples in gnomAD), is considered pathogenic (Bonn et al., 2010;Klebe et al., 2012;Sánchez Ferrero et al., 2013), likely with incomplete penetrance or variable expressivity. The high frequency of the p.(Ala510Val) variant, the wide clinical spectrum, and the possibility of dominant and recessive transmission make genetic counseling and correct diagnosis challenging in SPG7.
In the current study, we performed a comprehensive genetic analysis in a large cohort of HSP patients with either mono-allelic or bi-allelic variants in SPG7. We examined whether heterozygous SPG7 variants are overrepresented in HSP patients, and whether digenic inheritance of SPG7 variants together with other HSP-related gene variants may have a role in HSP.

Genetic and data analysis
DNA was extracted from peripheral blood using a standard salting-out procedure. In the HSP group, samples from 379 patients initially went through panel sequencing of HSP-associated genes. In total, 1,575 samples including 400 HSP and 1,175 control samples went through whole exome sequencing (WES). For exome target enrichment, SureSelect Human All Exon V4, V5, Nextera Rapid Capture Exomes and TruSeq Exome (Illumina) kits were used, and the sequencing was performed on Illumina HiSeq 2000/2500 platforms (San Diego, CA, USA). The sequence reads were aligned to the human reference genome (GRCh37/hg19) using Burrows-Wheeler Aligner (Li and Durbin, 2009). The calling of variants and annotation were done using Genome Analysis Toolkit and ANNOVAR, respectively (McKenna et al., 2010;Wang et al., 2010).
The initial selection of variants in the cohorts, was based on the identification of missense and protein truncating alleles in SPG7 (OMIM # 602783, NM_003119.3) with minor allele frequency less than 0.01 in the gnomAD (Karczewski et al., 2020). Using VarSome (Kopanos et al., 2019), the variants have been classified according to the American College of Medical Genetics and Genomics guidelines. The variants classified as "Likely Benign" and "Benign" were excluded from further analysis. The intronic splicing variants with uncertain significance higher than ±3 were also excluded. Then, we aimed to examine whether carriers of SPG7 variants may carry other variants in other HSP-associated genes or in genes linked to similar neurogenetic disorders which may involve spasticity. For this purpose, we searched for variants in 787 genes associated with such neurogenetic disorders (Supplementary Table 3) in HSP patients who carried at least one SPG7 allele. Variant calls with less than 30x depth of coverage, a genotype quality of less than 97 and less than 25% genotyping frequency were excluded from . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2020. . the analysis. All the detected variants were visually inspected with the Integrated Genomics Viewer and suspicious variants were validated using Sanger Sequencing. To check for relatedness in the control group and in HSP families with complex inheritance of SPG7, we used somalier (Pedersen et al., 2019). To test for the presence of population stratification within our cohort, we used PCA on filtered common variants from WES data. Genetic ancestry was determined by comparing it with HapMap (Nature, 2007).
Gene Ontology (GO) enrichment analysis was carried out using g:Profiler (Raudvere et al., 2019), with Benjamini-Hochberg adjusted p-values for statistical significance set at < 0.05.
For protein-protein interaction/network analysis, STRING (Szklarczyk et al., 2019) (without the Textmining feature) and GeneMANIA (Warde-Farley et al., 2010) were used. In order to predict the presence of important domains and sites of the corresponding protein, as well as multiple protein sequence alignment, we applied InterPro (Mitchell et al., 2019) and Clustal Omega tools, respectively (Sievers et al., 2011). A 3D atomic model of TBCE (a.a. 97-443) was built using the automated server I-TASSER (Yang et al., 2015). The model was derived from the coordinates of different LRR domains sharing 12-20% identity. A second model of the TBCE LRR domain (a.a. 97-347) was also built with SWISS-MODEL (Waterhouse et al., 2018) using the structure of the plant receptor BRI1 (pdb 3rj0, 33% sequence identity for this segment). The atomic coordinates of the TBC CAP-Gly domain (pdb 4b6m), TBCE Ubl domain (pdb 4icu) and human AFG3L2 (pdb 6nyy) were downloaded from the Protein Data Bank. The steric clashes induced by each mutation were evaluated using the "mutagenesis" toolbox in PyMol v. 2.3.5.
To study genotype-phenotype correlations in SPG7, we removed carriers of other pathogenic/likely pathogenic variants in HSP-related genes to avoid bias by other, non-SPG7 variants. We compared the following groups of patients: 1) carriers of homozygous variants, 2) . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2020. . carriers of compound heterozygous variants, and 3) carriers of heterozygous variants. Since it was previously suggested that HSP patients with the p.(Ala510Val) variant have a milder phenotype (Roxburgh et al., 2013), we also compared carriers of this variant to other SPG7 patients. In addition, due to the report of differences in clinical presentations between SPG7 patients with loss-of-function (LoF) and missense variants, patients were classified and compared based on the variant type including patients with: 1) one missense, 2) one LoF, 3) onemissense and one-LoF 4), two missense, and 5) two LoF variants.

Statistical analysis
For the analysis of binary variables, chi-square and Fisher's Exact test were used, and for continuous variables Mann-Whittney U and Kruskal-Wallis tests were used, as required. SPSS was used to perform all statistical analyses. For the genotype-phenotype analysis of symptoms, Bonferroni correction for multiple comparisons was applied and corrected p-value threshold was set to < 0.0005.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2020. .

Identification of bi-allelic and monoallelic SPG7 variant carriers with HSP
Out of 585 HSP patients, potentially pathogenic rare SPG7 variants were identified through either panel sequencing or WES in 38 patients (6.5%) with homozygous or compound heterozygous variants and in 21 patients (3.6%) with heterozygous variants. In order to further compare frequencies of SPG7 variants between patients and controls, we only included samples that went through WES, since controls did not go through panel sequencing, and since the panel sequencing did not always include SPG7. In index (unrelated) cases of HSP who underwent WES (n=291), 48 pathogenic/likely pathogenic SPG7 alleles were detected compared to 10 in unrelated controls (out of n=580) who went through WES (OR=11.25,p<0.0001 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

HSP
We further hypothesized that the overrepresentation of heterozygous SPG7 variants in HSP patients vs. controls could be due to digenic inheritance, i.e. that patients with heterozygous SPG7 variants may also carry variants in other HSP or similar neurogenetic disorders-associated genes (Supplementary Table 3). We found four index cases with heterozygous SPG7 variant who also carried pathogenic variants in other genes that are associated with spastic paraplegia/ataxia (  Table 2), which is known to cause Encephalopathy (OMIM # 617207) with spasticity. One of the two TBCE variants was annotated as pathogenic, while the other was annotated as likely benign. This patient presented with clinical features that fit both SPG7 and TBCE (Table 2). In addition, this patient presented with nephropathy and focal segmental glomerulosclerosis, which have not been previously reported in SPG7 and are a very rare clinical finding in HSP (Efstratiadis et al., 2006). We could not find a pathogenic variant in a gene related to nephropathy in this patient. Two other patients carried a SPAST mutation (Table 2). The average age at onset (AAO) of these four potentially digenic patients was 2.7 ± 2.1 y, compared to 28.0 ± 17.9 y in all other patients with SPG7 variants . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2020. .
To examine whether SPAST, BSCL2 and TBCE (the genes in which we found additional mutations in patients who also carry SPG7 heterozygous mutation, Table 2), are involved in specific cellular pathways in which SPG7 is also involved, we performed pathway enrichment analysis. We found enrichment mainly in axonal transport and cellular organization (adjusted p<0.05, Supplementary Table 5), with SPAST and SPG7 having the highest enrichment. Both SPAST and SPG7 play a major role in axonal transports and involved in biosynthesis, assembly and arrangement of macromolecules and cellular membrane and other components (Supplementary Table 5). Moreover, Spastin (SPG4) and Paraplegin (SPG7) contain the same ATPase domain where they participate in diverse cellular processes (IPR003959, IPR003593).
To identify additional patients who potentially have HSP due to digenic inheritance involving SPG7, we examined very rare variants (AF<0.001) in genes that produce proteins that interact with SPG7 (Supplementary Table 6). We found very rare heterozygous variants with uncertain significance in three genes (CACNA1A, AFG3L2and MORC2) in heterozygous carriers of SPG7 (Table 3). Among them, AFG3L2 had the closest interaction with SPG7 and both share similar features, including protein structure and domains, interacting proteins, and biological functions and pathways ( Figure 2). Except for one homozygous AFG3L2 variant (NM_006796), c.122G>A;(p.[Arg41Gln]) with gnomAD AF 0.00000481 (predicted as polymorphism by MutationTaster), which was identified in one control (who did not carry an SPG7 variant) out of 1,175, no rare variant was detected in CACNA1A, AFG3L2 and MORC2 genes in our controls.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2020. . Yet, to confirm their potential pathogenicity in digenic HSP, additional genetic and functional studies are needed.

Structural analysis of TBCE and AFG3L2 variants
Among the non-HSP genes that may contribute to oligogenic inheritance or epistasis, AFG3L2 and TBCE were the strongest candidates. To further examine whether the two TBCE variants identified in family 04-012 (Table 2) may be pathogenic we performed structural analysis of their potential effects on TBCE structure and function. The human tubulin cofactor E (TBCE) consists of a N-terminal CAP-Gly domain, followed by a leucine-rich repeat (LRR) domain and a C-terminal ubiquitin-like (Ubl) domain ( Figure 3A). The structures of TBCE alone and in complex with α-tubulin and TBCB were determined at low resolution by electron microscopy (Serna et al., 2015). The complex structure shows that α-tubulin binds to the CAP-Gly domain as well as the concave surface of the LRR domain. This interaction enables the TBCE-TBCB complex to dissociate the α/β tubulin heterodimers into monomers that can be degraded by the ubiquitin-proteasome system (Mi et al., 2009). To investigate the impact of the potential HSPrelated variant p.(Val221Leu) on TBCE's structure and function, we performed in silico mutagenesis of the residue in two homology models of TBCE. Val221 is located on the "exterior" side of the LRR domain, opposite to the side of interaction with tubulin ( Figure 3A). In the homology model generated with I-TASSER, the side-chain of Val221 points towards the solvent. The variant Val to Leu results in a clash with a helix in an adjacent repeat ( Figure 3B). In the homology model generated with SWISS-MODEL using the homologous LRR domain of the plant steroid hormone receptor BRI1 (pdb 3rj0, 33% sequence identity), Val221 is located in the hydrophobic core, and the p.(Val221Leu) variant also leads to steric clashes. In both models, our prediction is that the variant destabilizes the domain and might inactivate it. The mutation . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2020. . p.(Gln513Ter) would result in a 15 amino acid deletion in the Ubl domain of TBCE ( Figure 3A).
The crystal structure of the Ubl (pdb 4icu) shows that this segment comprises a helix and the Cterminal β strand, which is typically involved in protein-protein interactions (Trempe, 2011).
Deletion of this segment would therefore completely unfold the Ubl and disrupt its function. The Ubl domain might be involved in shuttling tubulin to the proteasome, given that the proteasome subunit Rpn10 binds to ubiquitin and Ubl domains (Riedinger et al., 2010;Chen et al., 2019).
However, the Ubl domain of TBCE has only 21% sequence identity with ubiquitin, and comparison of the TBCE Ubl with the complex of Rpn10 and the Ubl of UBQLN2 (14% sequence identity) reveals that most residues interacting with Rpn10 are not conserved between UBQLN2 and TBCE. Therefore, the TBCE Ubl is unlikely to bind to the proteasome. Its function thus remains unknown.
AFG3L2 is a subunit of the m-AAA protease complex, which cleaves proteins in the mitochondrial inner membrane (Koppen et al., 2007). It consists of a N-terminal segment that anchors them to the membrane, followed by an ATPase and protease domains that assemble into a hexamer. The structure of the soluble domains of human AFG3L2 bound to a substrate was determined by cryo-electron microscopy (cryo-EM) at high-resolution and revealed how its

Genotype-phenotype correlations among SPG7 mutation carriers
Next, we examined whether genotype-phenotype correlations exist between different groups of SPG7 variant carriers. Clinical data was available for 12 heterozygous carriers, 9 homozygous carriers (7 of whom are homozygous carriers of the p.(Ala510Val) variant), and 22 compound heterozygous carriers. Table 4 details the clinical data for each of these groups, each time comparing one group to the other two. After correction for multiple comparisons, there were no statistically significant differences between the groups. However, some differences between heterozygous carriers and bi-allelic variant carriers were notable. While upper extremity ataxia (37.9%) and intent tremor (30%) were relatively common in bi-allelic carriers of SPG7 variants, none of the heterozygous carriers showed these abnormalities. On the other hand, two heterozygous carriers presented with motor developmental delay which was not found in any biallelic patients. Moreover, patients with heterozygous SPG7 variants had younger AAO compared to bi-allelic patients (16.5 vs. 33.8 y, p=0.021). Cerebellar atrophy was the most common imaging finding among bi-allelic patients (22.7%).
We further examined whether there are differences between subgroup of patients, based on the type of variants that they carried (missense, loss-of-function) and the presence of the most common variant, p.(Ala510Val) which was carried by 34 (53.9%) of patients with at least one allele. No statistically significant differences were identified after correction for multiple . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2020. . Table 4, Supplementary Table 8), likely due to the small number of patients in each of these groups.

comparisons (
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2020. .

Discussion
The current study summarizes genetic and clinical data on SPG7 from a large Canadian cohort of 585 patients, of which 6.5% carried bi-allelic SPG7 variants. Our findings show that the number of pathogenic/likely pathogenic SPG7 alleles in HSP patients is higher than in controls, even when considering only heterozygous carriers in index HSP patients vs. unrelated controls, suggesting potential dominant or digenic inheritance in some cases. Along these lines, we found that some of the heterozygous carriers of SPG7 pathogenic variants with HSP also carried other potentially pathogenic variants in other genes, a phenomenon which was not observed in controls. These findings, which require replication, may suggest digenic inheritance in HSP associated with SPG7. Of note, we cannot rule out that in some of the heterozygous carriers of SPG7 variants, an additional SPG7 variant exists that was not detected through WES due to the limitation of WES to detect deep intronic and large structural variants.
The four patients with heterozygous SPG7 variants who also carried other variants in genes related to HSP phenotype had younger AAO (2.7 vs 28 y) and higher average SPRS score (37 vs 18.1), indicating that their disease is more severe than those who did not carry variants in two genes. Upper extremity weakness and hyperreflexia are relatively common in these potentially digenic patients compared to other carriers of mono-allelic and bi-allelic SPG7 alleles. We further examined the possibility of genetic interaction/modification by performing biological pathway enrichment analysis. SPAST and SPG7, whose variants co-occurred in three HSP patients, share a similar ATPase domain and closely interact in multiple pathways. In the control cohort, none of the participants carried pathogenic variants in the genes which were identified in the HSP patients (SPAST, BSCL2, and TBCE). Overall, these findings may suggest either digenic inheritance, or epistasis between heterozygous SPG7 variants and other HSP-. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2020. . related genes, as previously reported in SPG4 (Svenson et al., 2004;Erichsen et al., 2007;Newton et al., 2018). Digenic inheritance has been recently suggested in neurodegenerative disorders including spinocerebellar ataxia and Charcot-Marie-Tooth (CMT), when the diseases were initially considered as a simple Mendelian monogenic disorder (Figueroa et al., 2017;Nam et al., 2018). More recently, it was demonstrated that the EXOC4 gene may be involved in complex inheritance in axonopathies, including HSP and CMT (Bis-Brewer et al., 2020).
By combining interaction and genetic analyses, we have identified heterozygous carriers of SPG7 who also carried variants in genes potentially interacting with SPG7, including AFG3L2, CACNA1A, PNMA1 and MORC2. It is possible that the co-occurrence of the heterozygous variants of the above-mentioned genes with SPG7 heterozygous variants may lead to HSP. These results require replications in additional cohorts, as well as additional functional evidence. The pathway enrichment, domain prediction, protein network and protein conservational analysis showed that AFG3L2 is the strongest potential candidate interacting with SPG7. This finding is further supported by functional studies, demonstrating the potential interaction of these two proteins within the mitochondria (Martinelli et al., 2009;Patron et al., 2018). SPG7 and AFG3L2 exert overlapping substrate specificities, hence the expression level of AFG3L2 and SPG7 might be important in cell-type specificity in disorder. Dominant AFG3L2 mutations cause spinocerebellar ataxia type 28 (SCA28; OMIM # 610246) whereas biallelic mutation may affect the interaction of SPG7 and AFG3L2 and cause spastic ataxia 5 (SPAX; OMIM # 614487), a disease whose phenotype includes features of both SCA28 and SPG7. A recent study reported a patient with heterozygous variants in both genes with syndromic parkinsonism and optic atrophy (Magri et al., 2018). SPG7 and AFG3L2 are components of mitochondrial m-AAA proteases and they can assemble hetero-oligomeric proteolytic complexes . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2020. .
with SPG7 (Patron et al., 2018). Together with the findings in the current study, these data suggest that SPG7-AFG3L2 digenic variants may be a cause of HSP and similar disorders, and that individuals with heterozygous SPG7 variants with neurodegeneration should be specifically screened for AFG3L2 variants.
In this study we also report several rare clinical features of SPG7, including doparesponsive parkinsonism, dysphagia, dysmetria, jaw jerk, ptosis, ophthalmoplegia, optic atrophy and hands dystonia in bi-allelic SPG7 patients. A few studies previously reported some of these Our study has several limitations. Despite being one of the world's largest cohorts of HSP, the total number of SPG7 patients is still relatively small, especially for genotypephenotype studies. In addition, not all our HSP cohort went through WES, which prevented the participation of all patients in some of the analyses. One limitation of WES is that it cannot properly detect genetic variants such as large copy number variants (CNVs). While we did analyze the data with ExomeDepth (Plagnol et al., 2012), a computational tool for CNV detection in WES data, and did not identify CNVs, we cannot rule out that some of our supposedly heterozygous carriers of SPG7 variants carry an additional undetected SPG7 variant such as a large deletion.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2020. .
To conclude, our results suggest that the inheritance of SPG7 may be complex, and include dominant or digenic inheritance, on top of the known recessive inheritance. One of the most intriguing findings, which requires additional replications, is the potential digenic inheritance with AFG3L2 variants. The relatively high allele frequency of some of the pathogenic SPG7 variants in the general population, the results of the genotype-phenotype correlation analysis, and a recent functional study (Magri et al., 2018) support this possibility.
Future studies will benefit from whole genome sequencing, which will allow for identifying CNVs, and deep intronic variants that can lead to aberrant splicing, as well as for comprehensive investigation of complex inheritance in SPG7 and other forms of HSP.

Funding
This study was funded by CIHR Emerging Team Grant, in collaboration with the Canadian Organization for Rare Disorders (CORD), grant number RN127580 -260005, and by a CIHR Foundation grant granted to GAR. This research was undertaken thanks in part to funding from . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

Competing interests
The authors report no competing interests.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2020. .  Domain prediction by InterPro revealed that SPG7 and AFG3L2 share similar protein domains. The variant in AFG3L2 occurred in Peptidase M41 (IPR000642) which belongs to metallopeptidase families. D. Sequence alignment of AFG3L2 orthologs, showing conservation of Ile705. The AFG3L2 mutation occurred in an amino acid that is highly conserved among species. E. Network construction from SPG7 using GeneMANIA showed that AFG3L2 and SPG7 are partner proteins that interact with other genes in multiple pathways. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

Legends
The copyright holder for this this version posted September 27, 2020. .

Supplementary Tables and Figures
Supplementary Figure 1. The principal component analysis (PCA) on common variants was used to test for the presence of population stratification.  Table 5. Gene Ontology (GO) term enrichment with respect to Biological Process using g:Profiler. p values were corrected for multiple testing using the Benjamini-Hochberg false discovery rate. Adjusted p values show the significance of enrichment with the threshold of p<0.05. The data source from Gene Ontology with Biological Process (BP) subontology was used to describe in which biological process the gene product participates. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

Supplementary
The copyright holder for this this version posted September 27, 2020. . . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

References
The copyright holder for this this version posted September 27, 2020. .
P f  e  f  f  e  r  G  ,  G  o  r  m  a  n  G  S  ,  G  r  i  f  f  i  n  H  ,  K  u  r  z  a  w  a  -A  k  a  n  b  i  M  ,  B  l  a  k  e  l  y  E  L  ,  W  i  l  s  o  n  I   ,  e  t  a  l  .   M  u  t  a  t  i  o  n  s  i  n  t  h  e  S  P  G  7  g  e  n  e  c  a  u  s  e  c  h  r  o  n  i  c  p  r  o  g  r  e  s  s  i  v  e  e  x  t  e  r  n  a  l  o  p  h  t  h  a  l  m  o  p  l  e  g  i  a  t  h  r  o  u  g  h  d  i  s  o  r  d  e  r  e  d  m  i  t  o  c  h  o  n  d  r  i  a  l  D  N  A  m  a  i  n  t  e  n  a  n  c  e  .  2  0  1  4  ;  1  3  7  (  5  )  :  1  3  2  3  -3  6  .  P  l  a  g  n  o  l  V  ,  C  u  r  t  i  s  J  ,  E  p  s  t  e  i  n  M  ,  M  o  k  K  Y  ,  S  t  e  b  b  i  n  g  s  E  ,  G  r  i  g  o  r  i  a  d  o  u  S   ,  e  t  a  l  .   A  r  o  b  u  s  t  m  o  d  e  l  f  o  r  r  e  a  d  c  o  u  n  t  d  a  t  a  i  n  e  x  o  m  e  s  e  q  u  e  n  c  i  n  g  e  x  p  e  r  i  m  e  n  t  s  a  n  d  i  m  p  l  i  c  a  t  i  o  n  s  f  o  r  c  o  p  y  n  u  m  b  e  r  v  a  r  i  a  n  t  c  a  l  l  i  n  g  .  2  0  1  2  ;  2  8  (  2  1  )  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2020. . W  a  t  e  r  h  o  u  s  e  A  ,  B  e  r  t  o  n  i  M  ,  B  i  e  n  e  r  t  S  ,  S  t  u  d  e  r  G  ,  T  a  u  r  i  e  l  l  o  G  ,  G  u  m  i  e  n  n  y  R   ,  e  t  a  l  .   S  W  I  S  S  -M  O  D  E  L  :  h  o  m  o  l  o  g  y  m  o  d  e  l  l  i  n  g  o  f  p  r  o  t  e  i  n  s  t  r  u  c  t  u  r  e  s  a  n  d  c  o  m  p  l  e  x  e  s  .  2  0  1  8  ;  4  6  (  W  1  )  :  W  2  9  6  -W  3  0  3  .  Y  a  n  g  J  ,  Y  a  n  R  ,  R  o  y  A  ,  X  u  D  ,  P  o  i  s  s  o  n  J  ,  Z  h  a  n  g  Y  J  N  m  .  T  h  e  I  -T  A  S  S  E  R  S  u  i  t  e  :  p  r  o  t  e  i  n  s  t  r  u  c  t  u  r  e  a  n  d  f  u  n  c  t  i  o  n  p  r  e  d  i  c  t  i  o  n  .  2  0  1  5  ;  1  2  (  1  ) : 7 -8 .
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2020. .  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2020. . Table 3. Variants in SPG7 interacting genes which were identified in HSP patients with heterozygous SPG7 variants. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted September 27, 2020. .